Companies: 10,795·Total market cap: $144.5T
Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc.

ABOSNASDAQHealthcare● Active
$2.27
+$0.10(+4.52%)
Market Cap$137386529
P/E Ratio
52W High$3.6
52W Low$1.05
Overview

Acumen Pharmaceuticals, Inc. (ABOS) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · ABOS · as of Jun 9, 2026

Activity summary

Buy transactions

0

P-Purchase only

Sell transactions

44

12 Months

Buy/Sell ratio

0.00

Buy/Sell (by trades)

Overall sentiment

BEARISH
↑ Buy 0%Active transactions only · RSU vesting excluded100% Sell ↓

Acumen Pharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 9, 2026

ABOS insider buying and selling by quarter

ABOS insider selling · ABOS insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling
8.4M4.2M0
2025 Q2
2025 Q4
2026 Q1
2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 9, 2026

Active insiders

Most active in past 12 months · ABOS ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

ABOS executive sell shares · ABOS board member insider trading · ABOS insider trading SEC filing

Showing 72 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

RA CAPITAL MANAGEMENT, L.P.

Director

Award

Date

Jun 3

Shares

35,500

Price

Value

View Form 4 on SEC.gov

Fountain Nathan B

Director

Award

Date

Jun 3

Shares

35,500

Price

Value

View Form 4 on SEC.gov

Drapkin Kimberlee C

Director

Award

Date

Jun 3

Shares

35,500

Price

Value

View Form 4 on SEC.gov

Stalfort John A III

Director

Award

Date

Jun 3

Shares

35,500

Price

Value

View Form 4 on SEC.gov

Porter Derrell

Director

Award

Date

Jun 3

Shares

35,500

Price

Value

View Form 4 on SEC.gov

Ives Jeffrey L.

Director

Award

Date

Jun 3

Shares

35,500

Price

Value

View Form 4 on SEC.gov

Golumbeski George

Director

Award

Date

Jun 3

Shares

35,500

Price

Value

View Form 4 on SEC.gov

Stoppel Laura

Director

Award

Date

Jun 3

Shares

35,500

Price

Value

View Form 4 on SEC.gov

RA CAPITAL MANAGEMENT, L.P.

Director

Award

Date

Mar 16

Shares

6,060,606

Price

$3.30

Value

$20.00M ⚡

View Form 4 on SEC.gov

Meisner Derek M

Chief Legal Officer & Corp Sec

Option

Date

Mar 6

Shares

2,090

Price

$1.85

Value

$4K

View Form 4 on SEC.gov

Meisner Derek M

Chief Legal Officer & Corp Sec

Sale

Date

Mar 6

Shares

2,090

Price

$3.26

Value

$7K

View Form 4 on SEC.gov

Meisner Derek M

Chief Legal Officer & Corp Sec

Option

Date

Feb 27

Shares

9,406

Price

$1.85

Value

$17K

View Form 4 on SEC.gov

Meisner Derek M

Chief Legal Officer & Corp Sec

Sale

Date

Feb 27

Shares

9,406

Price

$3.01

Value

$28K

View Form 4 on SEC.gov

Meisner Derek M

Chief Legal Officer & Corp Sec

Option

Date

Jan 26

Shares

15,085

Price

$1.85

Value

$28K

View Form 4 on SEC.gov

Meisner Derek M

Chief Legal Officer & Corp Sec

Option

Date

Jan 28

Shares

2,671

Price

$1.85

Value

$5K

View Form 4 on SEC.gov

Meisner Derek M

Chief Legal Officer & Corp Sec

Sale

Date

Jan 28

Shares

2,671

Price

$3.00

Value

$8K

View Form 4 on SEC.gov

Meisner Derek M

Chief Legal Officer & Corp Sec

Sale

Date

Jan 26

Shares

15,085

Price

$3.00

Value

$45K

View Form 4 on SEC.gov

Meisner Derek M

Chief Legal Officer & Corp Sec

Sale

Date

Jan 21

Shares

2,247

Price

$1.81

Value

$4K

View Form 4 on SEC.gov

Meisner Derek M

Chief Legal Officer & Corp Sec

Sale

Date

Jan 22

Shares

1,054

Price

$1.84

Value

$2K

View Form 4 on SEC.gov

Meisner Derek M

Chief Legal Officer & Corp Sec

Sale

Date

Jan 23

Shares

5,633

Price

$1.90

Value

$11K

View Form 4 on SEC.gov

Siemers Eric

Chief Medical Officer

Sale

Date

Jan 21

Shares

2,331

Price

$1.80

Value

$4K

View Form 4 on SEC.gov

Siemers Eric

Chief Medical Officer

Sale

Date

Jan 22

Shares

895

Price

$1.82

Value

$2K

View Form 4 on SEC.gov

Zuga Matt

CFO & Chief Business Officer

Sale

Date

Jan 21

Shares

2,473

Price

$1.81

Value

$4K

View Form 4 on SEC.gov

Zuga Matt

CFO & Chief Business Officer

Sale

Date

Jan 22

Shares

1,687

Price

$1.86

Value

$3K

View Form 4 on SEC.gov

OConnell Daniel Joseph

CEO · Director

Sale

Date

Jan 21

Shares

9,346

Price

$1.81

Value

$17K

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 3

Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About ABOS insider trading

ABOS insider trades

Acumen Pharmaceuticals, Inc. (ABOS) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Meisner Derek M (Chief Legal Officer & Corp Sec), OConnell Daniel Joseph (CEO · Director), Zuga Matt (CFO & Chief Business Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. ABOS insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Acumen Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic
acquisitionOrDisposition field:
A = Acquisition (buy) · D = Disposition (sell)
RSU vesting (M-Exempt) excluded from sentiment
Form 4SEC filing required within 2 business days of any insider transaction
10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot
Open MktDirect purchase or sale on the open market (excludes awards, options)

Frequently asked questions

ABOS insider trading · 5 questions

The insiders of Acumen Pharmaceuticals, Inc. (ABOS) include executives and directors such as Meisner Derek M (Chief Legal Officer & Corp Sec), OConnell Daniel Joseph (CEO · Director), Zuga Matt (CFO & Chief Business Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

ABOS board member insider tradingwho are ABOS insidersABOS insider rosterAcumen Pharmaceuticals, Inc. executives insider activity

Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026